A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD for 72 months. This was an unusual case in which a serious side effect developed during a second ATD course. It is essential that clinicians remain vigilant to the fact that antithyroid drugs can induce agranulocytosis several years after initiated.

Cite

CITATION STYLE

APA

Kim, H., Lee, J., & Ha, J. (2018). A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves’ disease patient who was tolerant to the first ATD treatment. Clinical Case Reports, 6(9), 1701–1703. https://doi.org/10.1002/ccr3.1644

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free